RAS Clinical Trials in Hangzhou, Zhejiang
7 recruitingHangzhou, Zhejiang, China
Showing 1–7 of 7 trials
Recruiting
Phase 2
Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases
Colorectal, CancerKRAS G12C Mutant Advanced Solid TumorsFulzerasib+1 more
Zhejiang University40 enrolled1 locationNCT07581912
Recruiting
Phase 2
A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
Pancreatic CancerSolid TumorKRAS P.G12C
Allist Pharmaceuticals, Inc.88 enrolled31 locationsNCT06008288
Recruiting
Phase 1Phase 2
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
KRAS P.G12C
D3 Bio (Wuxi) Co., Ltd442 enrolled52 locationsNCT05410145
Recruiting
Phase 2
The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer
Colorectal NeoplasmsBRAFCetuximab+2 more
Zhejiang University70 enrolled1 locationNCT07257653
Recruiting
Phase 1Phase 2
A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
Advanced Solid TumorsKRAS G12D Mutations
Genfleet Therapeutics (Shanghai) Inc.407 enrolled20 locationsNCT06500676
Recruiting
Phase 1Phase 2
A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation
KRAS G12D Mutation
Ranok Therapeutics (Hangzhou) Co., Ltd.152 enrolled6 locationsNCT06667544
Recruiting
Phase 1Phase 2
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Colorectal, CancerNon-small Cell Lung CancerKRAS P.G12C+1 more
Allist Pharmaceuticals, Inc.240 enrolled27 locationsNCT05288205